Prof Andrew Owen BSc MSc PhD FSB

Professor Molecular and Clinical Pharmacology

    Biography

    Personal Statement

    Andrew Owen, Ph.D. FSB is a Professor in the Department of Molecular and Clinical Pharmacology. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. Professor Owen has contributed to over 110 original research and review publications, book chapters and patent applications. In recent years, research funding has been secured from the Medical Research Council, Engineering and Physical Sciences Research Council, US National Institutes of Health and the British Society for Antimicrobial Chemotherapy. He is Chair of the British Society for Nanomedicine. (www.BritishSocietyNanomedicine.org), a fellow of the Society of Biology and a member of the Nanomed Focus Group Steering Committee, British Pharmacological Society and Critical Path to TB Drug Regimens. Professor Owen is also a member of the editorial board for Nanomedicine: nanotechnology, biology and medicine.

    Personal Distinctions

    • Nanomedicine: What the clinician should know (University of Turin 2014)
    • Sustained Release Formulations for HIV Therapy (Invitation to Speak, American Society for Nanomedicine 2014)
    • Nanotechnology-enabled therapies for improved delivery of antiretroviral drugs (University of Cambridge 2014)
    • Improved Oral Delivery of Antiretroviral Drugs Via A Novel Synthesis of Solid Drug Nanoparticle Form (Invitation to Speak, British Society For Nanomedicine / SelectBio 2014)
    • A flexible and scalable alternative to nanomilling for formation of solid drug nanoparticles (Invitation to Speak, NIH/DAIDS 2014)
    • Opportunities and challenges in development of solid drug nanoparticles for HIV treatment (Centre de Recherche Public de la Santé 2014)
    • The application of nanotechnology for optimisation of antiretroviral drug delivery (Invitation to Speak, CLINAM 2014)
    • Nanomedicine in HIV: which perspectives? (Invitation to Speak, University of Turin 2013)
    • The importance of studying drug transporters in HCV drug development (Invitation to Speak, HCV Drug Development Advisory Group 2013)
    • The impact of hepatic transporters and pharmacogenetics on the pharmacokinetics of anti-HCV drugs (Invitation to Speak, The International Liver Congress 2013)
    • What potential role will novel oral formulations (nanoformulations and nanotechnology) play in HIV (Invitation to Speak, CADO2 2013)
    • How to Target HIV with Nanomedicine (Invitation to Speak, European AIDS Society 2013)
    • Iterating synthesis with pharmacology to accelerate nanomedicine development (Invitation to Speak, British Pharmacological Society 2013)
    • The role of drug transporters in pharmacokinetics, DDIs and safety of antiretrovirals (Invitation to Speak, Merck 2013)
    • Improved pharmacokinetics of antiretroviral drugs through formation of solid drug nanoparticles (Invitation to Speak, Pharmacokinetics UK 2013)
    • Emerging technologies and challenges for development of long acting therapies (Invitation to Speak, NIH/NIAID/DHHS 2013)
    • Integrated Early Assessment of Nano-particle Risks and Benefits (Invitation to Speak, 4th Georgia Symposium on Nanotechnology and Infectious Diseases, Atlanta, USA 2012)
    • Pharmacological assessment of antiretroviral solid drug nanoparticles (Invitation to Speak, Herriot Watt University, Edinburgh, UK 2012)
    • Little Big Medicine (Invitation to Speak, International Society on Thrombosis and Haemostasis (ISTH) conference, BT Convention Centre, Liverpool, UK 2012)
    • The role of influx and efflux transporters in pharmacokinetics, distribution and safety of antiretro (Invitation to Speak, Merck Global Therapeutics Expert forum, Philadelphia, USA 2012)
    • Application of solid drug nanoparticles to treatment of Human Immunodeficiency Virus infection (Invitation to Speak, New frontiers: Inaugural meeting of the British Society for Nanomedicine, the Athenaeum, Liverpool, UK 2012)
    • Nanotechnology and Medicine (Invitation to Speak, Liverpool Life Sciences Network - Spring Networking Event, Hard Days Night Hotel, Liverpool, UK 2012)
    • Recent advances in pharmacogenetics of antiretroviral therapy (Invitation to Speak, University of Belgrade, Belgrade, Serbia 2012)
    • How can we solve the problem of second – line HIV and TB drug interactions? (Invitation to Speak, Médecins Sans Frontières Campaign for Access to Essential Medicines – ART Sequencing Workshop, Geneva, Switzerland 2011)
    • Pharmacogenomics (Invitation to Speak, 6th Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy. 2011)
    • Insight into the Pharmacogenetics of Clinically Important Drug Transporters (Invitation to Speak, World Drug Transporter Summit, Boston, USA 2011)
    • Pharmacogenomics and Antimicrobial Agents (Invitation to Speak, 29th Annual meeting of the European Society for Paediatric Infectious Diseases, The Hague, Netherlands 2011)
    • The application of nanotechnology to improve bioavailability of antiretroviral drugs (Invitation to Speak, 12th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, Florida, USA 2011)
    • Non-attrition nanoparticles for delivery of antiretroviral drugs (Invitation to Speak, University of Nebraska Medical Centre, Omaha, USA 2011)
    • Use of nanomaterials in drug delivery systems (Invitation to Speak, Modular Training Programme in Applied Toxicology, Nanotoxicology, University of Surrey, Guilford, UK 2011)
    • The application of nanotechnology to improve bioavailability of antiretroviral drugs (Modular Training Programme in Applied Toxicology, Nanotoxicology, University of Surrey, Guilford, UK 2011)
    • Using Transporter Pharmacogenetics to Improve Patient Care. (Invitation to Speak, Clinically Relevant Drug Transporters, CCT Venues Canary Wharf, London UK 2010)
    • Pharmacogenetic determinants of response to therapy of HIV infection. (Invitation to Speak, Molecular Diagnostics 2010, Moscow, Russia 2010)
    • Nanoparticles for oral antiretroviral drug delivery: balancing efficacy and safety. (Invitation to Speak, The DAIDS Workshop: Nano & Emerging Technologies for HIV 2010)
    • The Impact of Pharmacogenetics on Variability in Drug Disposition. (Invitation to Speak, Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, USA 2010)
    • HIV drug disposition: a pharmacogenetic perspective (Invitation to Speak, Harvard School of Public Health, Program for HIV Prevention and Treatment, Chiang Mai, Thailand 2010)
    • Transporter pharmacogenetics - from bench to bedside and back again (Invitation to Speak, DMDG Open Meeting, University of Kent, Canterbury, UK 2010)
    • Nanoparticle Delivery of Antiretroviral Drugs: Opportunities and Safety Concerns. (Invitation to Speak, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK. 2010)
    • Pharmacogenetics – Upcoming Applications to Patient Care. (Invitation to Speak, 17th Conference on Retroviruses and Opportunistic Infections (CROI), San Francisco, USA. 2010)
    • Pharmacogenetics and pharmacogenomics. (Invitation to Speak, 4th Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy. 2009)
    • HIV therapy- New Insights in Pharmacogenetics and Pharmokinetics (Invitation to Speak, Klinik I für Inneren Medizin, Cologne, Germany 2009)
    • Nanotechnology-based medicinal products for human use-current issues and future developments. (Invitation to Speak, British Toxicology Society Autumn meeting. 2009)
    • Pharmacogenetics and antiretrovirals: an African Perspective. (Invitation to Speak, UK-Ghana Royal Society HIV workshop 2008)
    • Investigating the mechanisms of variability in antiretroviral pharmacokinetics. (Invitation to Speak, Ottawa Health Research Institute, Ottawa, Ontario, Canada. 2008)
    • Inter-individual variability in drug disposition (Invitation to Speak, AstraZeneca R&D Charnwood 2008)
    • The role of nuclear receptors in drug metabolism and disposition. (Invitation to Speak, School of Biomedical Sciences, University of Ulster, Coleraine campus, Cromore Road, Coleraine, Co. Londonderry. 2007)
    • HIV Pharmacology (Invitation to Speak, Liverpool School of Tropical Medicine 2007)
    • Pharmocogenomics (Invitation to Speak, British Association for Sexual Health and HIV spotlight meeting, London, UK. 2007)
    • Pharmacogenetics of HIV therapy. (Invitation to Speak, Abbott symposium at the BHIVA spring meeting, London, UK. 2007)
    • 2007 SAGE LECTURER OF THE YEAR (WORLD LEADERSHIP FORUM 2007)
    • Pharmacogenetics and pharmacogenomics (Invitation to Speak, 3rd Residential Course on Clinical Pharmacology of Antiretrovirals, Torino, Italy 2007)
    • Presentation ranked in the top 5 for the Pharmacology section (13th conference on retroviruses and opportunistic infections 2006)
    • Host Determinants of Antiretroviral Treatment Response. (Invitation to Speak, Molecular and Biochemical Parasitology Research Retreat, Whinfell Forest, UK. 2006)
    • Host factors influencing variability in response to antiretroviral drugs. (Invitation to Speak, Shenyang Pharmaceutical University, LiaoNing, P.R.China. 2006)
    • Induction of Intestinal and Hepatic Disposition Genes by Paradigm Nuclear Receptor Ligands (Invitation to Speak, AstraZeneca R&D Charnwood, Loughborough, Leics, UK 2005)
    • Presentation ranked in the top 5 for the Pharmacology section (12th conference on retroviruses and opportunistic infections 2005)
    • In vitro interaction between mefloquine and saquinavir: The role of breast cancer resistance protein (Invitation to Speak, 5th Colloquium of the University of Liverpool Centre for Comparative Infectious Diseases, Liverpool, UK 2004)
    • Pharmacogenetics of Drug Transport / Metabolism in HIV therapy (Invitation to Speak, South West Clinical Pharmacology Meeting, Southampton, UK 2004)
    • Relationship between drug transporters and chemokine receptors: relevance to UK-427, 857 (Invitation to Speak, Pfizer central Research, Sandwich, Kent, UK 2004)
    • Presentation ranked in the top 5 for the Pharmacology section (11th conference on retroviruses and opportunistic infections 2004)
    • Presentation ranked in the top 5 for the Pharmacology section (10th conference on retroviruses and opportunistic infections 2003)
    • The reciprocal role of transporters and chemokine receptors on drug response (Invitation to Speak, College of Pharmacy, Duluth, University of Minnesota, Minneapolis, MN, USA 2003)
    • The reciprocal role of transporters and chemokine receptors on drug response (Invitation to Speak, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA 2003)
    • Winner of the Best Oral Communication in the Clinical Section (Prize, British Pharmacological Society 2000)

    Administrative Roles

    • Professor Owen is Chair of the British Society for Nanomedicine (www.BritishSocietyNanomedicine.org), a member of several committees within the University and is the manager of the Departmental Containment Level III facility.

    Untitled Document